SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila Healthcare rises on getting USFDA’s nod for Amiloride Hydrochloride Tablets

11 Aug 2015 Evaluate

Cadila Healthcare is currently trading at Rs. 1915.00, up by 18.20 points or 0.96% from its previous closing of Rs. 1896.80 on the BSE.

The scrip opened at Rs.1900.85 and has touched a high and low of Rs.1935.00 and Rs.1897.75 respectively. So far 9475 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2045.00 on 17-Jul-2015 and a 52 week low of Rs. 1075.45 on 12-Aug-2014.

Last one week high and low of the scrip stood at Rs. 1960.00 and Rs. 1846.00 respectively. The current market cap of the company is Rs. 39225.72 crore.

The promoters holding in the company stood at 74.79% while Institutions and Non-Institutions held 15.04% and 10.17% respectively.

Zydus Cadila has received the final approval from the USFDA to market Amiloride Hydrochloride Tablets USP, 5 mg. The drug falls in the diuretics segment. The group now has 101 approvals and has so far filed over 260 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

Zydus Lifesciences Share Price

942.55 3.35 (0.36%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×